Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Senthil Kumar Manoharan

Showing results (1-10 of 4) with videos related to

Pageof 1
Sort By:
Thescientificworldjournal|July 30, 2015
Personal Authentication Using Multifeatures Multispectral Palm Print TraitsGayathri Rajagopal, Senthil Kumar Manoharan
Ebiomedicine|August 15, 2022
Evaluation of safety and immunogenicity of receptor-binding domain-based COVID-19 vaccine (Corbevax) to select the optimum formulation in open-label, multicentre, and randomised phase-1/2 and phase-2 clinical trialsSubhash Thuluva, Vikram Paradkar, Subba Reddy Gunneri, et al.
Vaccine|November 3, 2022
Safety, tolerability and immunogenicity of Biological E's CORBEVAX™ vaccine in children and adolescents: A prospective, randomised, double-blind, placebo controlled, phase-2/3 studySubhash Thuluva, Vikram Paradkar, SubbaReddy Gunneri, et al.
Human Vaccines & Immunotherapeutics|April 28, 2023
Immunogenicity and safety of Biological E's CORBEVAX™ vaccine compared to COVISHIELD™ (ChAdOx1 nCoV-19) vaccine studied in a phase-3, single blind, multicentre, randomized clinical trialSubhash Thuluva, Vikram Paradkar, SubbaReddy Gunneri, et al.
Pageof 1

Showing results (1-10 of 4) with videos related to

Sort By:
Pageof 1
Thescientificworldjournal|July 30, 2015
Personal Authentication Using Multifeatures Multispectral Palm Print TraitsGayathri Rajagopal, Senthil Kumar Manoharan
Ebiomedicine|August 15, 2022
Evaluation of safety and immunogenicity of receptor-binding domain-based COVID-19 vaccine (Corbevax) to select the optimum formulation in open-label, multicentre, and randomised phase-1/2 and phase-2 clinical trialsSubhash Thuluva, Vikram Paradkar, Subba Reddy Gunneri, et al.
Vaccine|November 3, 2022
Safety, tolerability and immunogenicity of Biological E's CORBEVAX™ vaccine in children and adolescents: A prospective, randomised, double-blind, placebo controlled, phase-2/3 studySubhash Thuluva, Vikram Paradkar, SubbaReddy Gunneri, et al.
Human Vaccines & Immunotherapeutics|April 28, 2023
Immunogenicity and safety of Biological E's CORBEVAX™ vaccine compared to COVISHIELD™ (ChAdOx1 nCoV-19) vaccine studied in a phase-3, single blind, multicentre, randomized clinical trialSubhash Thuluva, Vikram Paradkar, SubbaReddy Gunneri, et al.
Pageof 1